Fig. 5.

Impact of minimal residual disease status on survival by FLT3-PCR [A-B] and multiparametric flow cytometry [C-D]) in cohort 2 (relapsed/refractory) patients who achieved a CRc. In cohort 2 (relapsed/refractory), among the responders with FLT-ITD PCR checked at the time of CRc, patients who achieved minimal residual disease (MRD) negativity by FLT3 RT-PCR had improved OS and EFS (a, b). In contrast, there was no significant impact of achieving MRD negativity by multiparametric flow cytometry (C and D) on OS and EFS in R/R FLT3-mutated AML treated with FLT3i-based therapies